Skip to content

NT-proBNP as a marker of coronary artery disease burden in chronic coronary syndromes.

Aug 2026 · International Journal of Cardiology · Vol 463, pp. 134752 · 0 citations · 13 references
Medicine

TL;DR

NT-proBNP was independently associated with obstructive CAD and correlated with coronary disease burden, however, its modest discriminatory performance precludes its use as a stand-alone diagnostic test for high-risk coronary anatomy.

Abstract

Background

Evidence regarding the role of N-terminal pro-brain natriuretic peptide (NTproBNP) in chronic coronary syndrome (CCS) remains limited. We aimed to investigate the association between plasma NTproBNP levels and the presence and extent of coronary artery disease (CAD) in a prospective real-world cohort.

Methods

This prospective observational cross-sectional study included 676 consecutive patients (mean age 67 ± 7 years; 20% women) referred for elective coronary angiography for suspected CCS, as part of the BNP-CAD study (ClinicalTrials.govNCT07013344). Patients with conditions known to elevate NTproBNP were excluded. Obstructive CAD was defined as stenosis ≥70% (≥50% for the left main). Prognostically significant CAD was defined as involvement of the left main or proximal LAD artery.

Results

Obstructive CAD was identified in 432 patients (64%). NTproBNP levels were significantly higher in patients with obstructive CAD compared to those without (124 vs. 96 pg/mL, p < 0.001) and increased with the number of vessels involved and degree of stenosis. After adjustment for clinical confounders and high-sensitivity troponin T, NT-proBNP remained independently associated with obstructive CAD (OR per 100 pg/mL increase: 1.18; 95% CI: 1.03-1.36; p = 0.021). Prognostically significant CAD was present in 197 patients (46% of those with obstructive CAD) and was associated with higher NT-proBNP levels (133 vs. 107 pg/mL; p = 0.006), although discriminatory performance remained modest (AUC: 0.60; 95% CI: 0.55-0.64).

Conclusion

NT-proBNP was independently associated with obstructive CAD and correlated with coronary disease burden. However, its modest discriminatory performance precludes its use as a stand-alone diagnostic test for high-risk coronary anatomy.

View source

Similar papers

Open access Sep 2026

Assessment of the dynamics of cardiological markers (LV systolic function, NT-proBNP) and its relationship with actual adherence to drug therapy in patients with stable coronary artery disease after planned myocardial revascularization

Objective: to evaluate the dynamics of left ventricular ejection fraction (LVEF) and N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients with stable coronary artery disease (CAD) before and after planned myocardial revascularization and to analyze their association with actual adherence to drug therapy....

Yu. V. Nefedochkin, G. Ignatenko · 0 citations
Open access Aug 2026

The use of natriuretic peptide to screen for stage B heart failure based on echocardiogram among cancer survivors

Heart failure is a progressive disorder that can be identified at earlier stage, also known as stage B heart failure (SBHF). While N-terminal pro-B-type natriuretic peptide (NT-proBNP) was shown to be a key biomarker, its screening performance among cancer survivors remains uncertain. This study aimed to identify...

Cheng Hwee Soh, Joshua Wong, Guang-Li Zhu et al. · 0 citations
Open access Aug 2026

Personalized evaluation of NT-proBNP and clinical characteristics in suspected heart failure: the PRECISE-HF study.

BACKGROUND AND AIMS N-terminal pro-B-type natriuretic peptide (NT-proBNP) is recommended to guide echocardiography referral in community-based patients with suspected heart failure (HF), but diagnostic performance is influenced by individual characteristics including age, ethnicity, kidney function, cardiac rhythm, and...

K. Docherty, B. Heywood, L. Anderson et al. · 0 citations
Open access Sep 2026

The impact of changes in N-terminal pro-B-type natriuretic peptide on the outcome of acute kidney injury in patients with ST-segment elevation myocardial infarction after percutaneous coronary intervention: a retrospective study.

BACKGROUND Patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI) are at heightened risk of acute kidney injury (AKI). Prior studies have suggested that serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) may be linked to AKI development, proposing i...

Chong-Rong Qiu, Wei Zhan · 0 citations
Open access Sep 2026

Predictive Value of the Triglyceride–Glucose Index for Major Adverse Cardiovascular Events in Patients with Premature Coronary Artery Disease

The admission TyG index did not show a statistically significant relationship with coronary anatomical severity or long-term clinical outcomes in premature CAD, and risk assessment in acute coronary patients should continue to prioritize established clinical, acute inflammatory, and angiographic parameters.

Saadet Bülüç, F. Akın, Oğuzhan Çelik et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.